Compare S&P Global Inc (SPGI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P Global Inc vs Viatris Inc — how do they compare? S&P Global Inc trades at $407.82 (market cap $118.72B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: S&P Global Inc is far larger — about 5.9× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold S&P Global Inc for 123 Days and Viatris Inc for 57 Days on average.
| SPGI | VTRS | |
|---|---|---|
Market Cap | $118.72B | $20.03B |
Volume | 1,647,917 | 14,109,977 |
Sector | Financials | Health |
52-Week High | $517.92 | $18.27 |
52-Week Low | $370.42 | $9.74 |
Typical Hold Time | 123 Days | 57 Days |
Enterprise Value | $130.21B | $32.15B |
Dividend Yield | 0.96% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
S&P Global (SPGI) trades at $407.82, up 3.2% today, with a bearish technical signal despite strong fundamentals. Revenue grew to $15.34B in 2025, with a net income margin of 30.54%. Recent news highlights expansion into digital asset risk assessment and AI-driven growth, while analyst consensus remains strongly bullish with a $509.50 price target.
The outlook is positive given robust earnings beats, high profitability, and strategic acquisitions, but risks include rising debt levels and market volatility. Wall Street's buy ratings (85.71%) support upside potential, though technical resistance near $409 may limit near-term gains.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
